

ASX RELEASE

20 January 2020

### Amplia Therapeutics Undertakes Placement

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to announce it has successfully undertaken a share placement to new and existing professional and sophisticated investors, which included a cornerstone investment on behalf of the Platinum International Healthcare Fund, one of Australia’s leading biotechnology investors.

The placement of 13.3 million new fully paid ordinary shares at \$0.07 per share to raise \$0.93 million before costs (the “Placement”) is being made within the Company’s placement capacity under ASX listing rules 7.1 and 7.1A. The Placement price represents a 12.5% discount to the last traded price on 15 January and a 6.3% discount to the 10 day volume weighted price of shares traded until 15 January.

The new capital will enable the Company to complete the clinic-enabling studies that were initiated using the funds raised during 2019. The Company remains on track to initiate clinical trials of its lead FAK inhibitor, AMP945, during 2020.

Commenting on the placement, Amplia’s Chief Executive Officer Dr John Lambert said “We are delighted to have completed this placement as it will allow us to drive our FAK assets into the clinic. We are particularly pleased to see the participation in the placement of such highly regarded investors as Platinum and see this as a strong endorsement of the potential of Amplia’s FAK assets and the team we have put in place.”

Taylor Collison acted as Lead Manager to the Placement.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

#### For Further Information

Dr. John Lambert  
Chief Executive Officer  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

#### About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).